Procalcitonin in surgery

1. Clinical Utility of Procalcitonin and C-Reactive Protein as Predictive
biological Markers in Esophageal Atresia Surgery
Materials and cohort
Peri-operative trends of procalcitonin and
C-Reactive Protein were assessed in
patients with esophageal atresia (n=23)
POD-5 procalcitonin cut-off @
1.38 ng/ml predicted the possibility
of a major complication with a sensitivity of
83.3 % and a specificity of 93.3 %.
Baseline serum procalcitonin level
was elevated in 18/23 (78.3%) patients
POD-1 procalcitonin depicted a 183.5%
rise followed by a gradual decline
Conclusions: Procalcitonin is a good indicator to identify the
adverse events in neonates after surgery for esophageal atresia.
POD-1 procalcitonin correlated with
survival.
Baseline and POD-5 serum procalcitonin
correlated with clinical outcomes.
POD-1 procalcitonin cut-off @ 3.29 ng/ml
predicted mortality with sensitivity and
specificity of 100 % and 57.9 % .
Mahajan et al., 2021
Findings Outcome
Patients who sustained major complications
(6/8; 75%) depicted a change in serum
procalcitonin trend 24-48 hours ahead of
clinical manifestation of an adverse event.
The procalcitonin levels in patients who sustained a
major complication depicted a reversal in trend 24-48
hours of clinical manifestation.